Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

When Can We Discharge Differentiated Thyroid Cancer Patients Who Present With High-Risk Disease and Subsequently Have an Excellent Response to Treatment?

Mulla O, Seejore K, Gerrard GE, Gill VM, Murray RD.

Clin Oncol (R Coll Radiol). 2019 Oct;31(10):733-734. doi: 10.1016/j.clon.2019.06.016. Epub 2019 Jul 17. No abstract available.

PMID:
31326145
2.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 Dec;104(12):2400-2409. doi: 10.3324/haematol.2018.200220. Epub 2019 May 9.

3.

Pushing the boundaries of in situ hybridisation for mRNA demonstration: demonstration of kappa and lambda light chain restriction in follicular lymphoma.

Warford A, Rahman M, Hughes JA, Gerrard G, Ribeiro DA.

Br J Biomed Sci. 2019 Jul;76(3):143-146. doi: 10.1080/09674845.2019.1598100. Epub 2019 Apr 26. No abstract available.

PMID:
30892145
4.

Differentiated Thyroid Cancer in Children: A UK Multicentre Review and Review of the Literature.

Lee KA, Sharabiani MTA, Tumino D, Wadsley J, Gill V, Gerrard G, Sindhu R, Gaze MN, Moss L, Newbold K.

Clin Oncol (R Coll Radiol). 2019 Jun;31(6):385-390. doi: 10.1016/j.clon.2019.02.005. Epub 2019 Mar 14.

PMID:
30878210
5.

Hypothalamic-pituitary axis irradiation dose thresholds for the development of hypopituitarism in adult-onset gliomas.

Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Short SC, Loughrey C, Murray RD.

Clin Endocrinol (Oxf). 2019 Jul;91(1):131-140. doi: 10.1111/cen.13971. Epub 2019 Apr 16.

PMID:
30873631
6.

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1.

Pfeifer H, Cazzaniga G, van der Velden VHJ, Cayuela JM, Schäfer B, Spinelli O, Akiki S, Avigad S, Bendit I, Borg K, Cavé H, Elia L, Reshmi SC, Gerrard G, Hayette S, Hermanson M, Juh A, Jurcek T, Chillón MC, Homburg C, Martinelli G, Kairisto V, Lange T, Lion T, Mueller MC, Pane F, Rai L, Damm-Welk C, Sacha T, Schnittger S, Touloumenidou T, Valerhaugen H, Vandenberghe P, Zuna J, Serve H, Herrmann E, Markovic S, Dongen JJMV, Ottmann OG.

Leukemia. 2019 Aug;33(8):1910-1922. doi: 10.1038/s41375-019-0413-0. Epub 2019 Mar 11.

PMID:
30858550
7.

Targeted next generation sequencing of pancreatic solid pseudopapillary neoplasms show mutations in Wnt signaling pathway genes.

Wang J, Gerrard G, Poskitt B, Dawson K, Trivedi P, Foroni L, El-Bahrawy M.

Pathol Int. 2019 Apr;69(4):193-201. doi: 10.1111/pin.12778. Epub 2019 Feb 27.

PMID:
30811747
8.

Can we predict long-term survival in resectable pancreatic ductal adenocarcinoma?

Gall TMH, Gerrard G, Frampton AE, Castellano L, Ahmad R, Habib N, Spalding D, Pai M, Foroni L, Jiao LR.

Oncotarget. 2019 Jan 22;10(7):696-706. doi: 10.18632/oncotarget.26511. eCollection 2019 Jan 22.

9.

Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?

Seejore K, Gerrard GE, Gill VM, Murray RD.

Clin Oncol (R Coll Radiol). 2019 Apr;31(4):219-224. doi: 10.1016/j.clon.2019.01.005. Epub 2019 Feb 7.

PMID:
30744934
10.

An investigation into the variability of primary care oral surgery contracts and tariffs in England and Wales (2014/2015).

Hierons RJ, Gerrard G, Jones R.

Br Dent J. 2017 Jun 9;222(11):870-877. doi: 10.1038/sj.bdj.2017.500. Erratum in: Br Dent J. 2017 Aug 11;223(3):234.

PMID:
28703178
11.

How did we do? An investigation into the suitability of patient questionnaires (PREMs and PROMs) in three primary care oral surgery practices.

Gerrard G, Jones R, Hierons RJ.

Br Dent J. 2017 Jul 7;223(1):27-32. doi: 10.1038/sj.bdj.2017.582.

PMID:
28684839
12.

Ten Year Experience of Radioiodine Dosimetry: is it Useful in the Management of Metastatic Differentiated Thyroid Cancer?

Sun F, Gerrard GE, Roberts JK, Telford T, Namini S, Waller M, Flux G, Gill VM.

Clin Oncol (R Coll Radiol). 2017 May;29(5):310-315. doi: 10.1016/j.clon.2017.01.002. Epub 2017 Jan 27.

PMID:
28132755
13.

Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.

Bond J, Domaschenz R, Roman-Trufero M, Sabbattini P, Ferreiros-Vidal I, Gerrard G, Asnafi V, Macintyre E, Merkenschlager M, Dillon N.

Oncotarget. 2016 Oct 4;7(40):65923-65936. doi: 10.18632/oncotarget.11688.

14.

Cepheid xpert monitor platform for the confirmation of BCR-ABL1 IS conversion factors for the molecular monitoring of chronic myeloid leukaemia.

Gerrard G, Foong HE, Mudge K, Alikian M, Apperley JF, Foroni L.

Leuk Res. 2016 Oct;49:47-50. doi: 10.1016/j.leukres.2016.08.007. Epub 2016 Aug 13.

PMID:
27552679
15.

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale.

Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S.

Leukemia. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. Epub 2016 Apr 25.

16.

Assessing the use of the Index of Sedation Need in oral surgery.

Gerrard G.

Br Dent J. 2016 Mar 25;220(6):295-8. doi: 10.1038/sj.bdj.2016.219.

PMID:
27012345
17.

Cancer Multidisciplinary Teams can be a Valuable and an Effective Use of a Clinician's Time.

Sun F, Gerrard G.

Clin Oncol (R Coll Radiol). 2016 Jun;28(6):410. doi: 10.1016/j.clon.2016.01.015. Epub 2016 Feb 12. No abstract available.

PMID:
26880061
18.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG.

J Mol Diagn. 2016 Mar;18(2):176-89. doi: 10.1016/j.jmoldx.2015.09.005. Epub 2016 Feb 5.

19.

Pituitary dysfunction following cranial radiotherapy for adult-onset nonpituitary brain tumours.

Kyriakakis N, Lynch J, Orme SM, Gerrard G, Hatfield P, Loughrey C, Short SC, Murray RD.

Clin Endocrinol (Oxf). 2016 Mar;84(3):372-9. doi: 10.1111/cen.12969. Epub 2015 Nov 24.

PMID:
26501843
20.

Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs.

Iskander D, Psaila B, Gerrard G, Chaidos A, En Foong H, Harrington Y, Karnik LC, Roberts I, de la Fuente J, Karadimitris A.

Blood. 2015 Apr 16;125(16):2553-7. doi: 10.1182/blood-2014-10-608042. Epub 2015 Mar 9.

PMID:
25755292
21.

Anaesthesia: over prescription.

Renton T, Gerrard G, Obisesan O, Jackson I.

Br Dent J. 2015 Feb 16;218(3):92. doi: 10.1038/sj.bdj.2015.58. No abstract available.

PMID:
25686411
22.

PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.

Alonso-Dominguez JM, Grinfeld J, Alikian M, Marin D, Reid A, Daghistani M, Hedgley C, O'Brien S, Clark RE, Apperley J, Foroni L, Gerrard G.

Am J Hematol. 2015 Jan;90(1):20-6. doi: 10.1002/ajh.23857. Epub 2014 Oct 18.

23.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR.

White H, Deprez L, Corbisier P, Hall V, Lin F, Mazoua S, Trapmann S, Aggerholm A, Andrikovics H, Akiki S, Barbany G, Boeckx N, Bench A, Catherwood M, Cayuela JM, Chudleigh S, Clench T, Colomer D, Daraio F, Dulucq S, Farrugia J, Fletcher L, Foroni L, Ganderton R, Gerrard G, Gineikienė E, Hayette S, El Housni H, Izzo B, Jansson M, Johnels P, Jurcek T, Kairisto V, Kizilors A, Kim DW, Lange T, Lion T, Polakova KM, Martinelli G, McCarron S, Merle PA, Milner B, Mitterbauer-Hohendanner G, Nagar M, Nickless G, Nomdedéu J, Nymoen DA, Leibundgut EO, Ozbek U, Pajič T, Pfeifer H, Preudhomme C, Raudsepp K, Romeo G, Sacha T, Talmaci R, Touloumenidou T, Van der Velden VH, Waits P, Wang L, Wilkinson E, Wilson G, Wren D, Zadro R, Ziermann J, Zoi K, Müller MC, Hochhaus A, Schimmel H, Cross NC, Emons H.

Leukemia. 2015 Feb;29(2):369-76. doi: 10.1038/leu.2014.217. Epub 2014 Jul 18.

24.

Real-time quantification assay to monitor BCR-ABL1 transcripts in chronic myeloid leukemia.

Foskett P, Gerrard G, Foroni L.

Methods Mol Biol. 2014;1160:115-24. doi: 10.1007/978-1-4939-0733-5_11.

PMID:
24740226
25.

Printed radiographs--is what you see what you get?

Gerrard G.

Dent Update. 2013 Oct;40(8):637-8, 641.

PMID:
24279216
26.

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Fielding AK, Rowe JM, Buck G, Foroni L, Gerrard G, Litzow MR, Lazarus H, Luger SM, Marks DI, McMillan AK, Moorman AV, Patel B, Paietta E, Tallman MS, Goldstone AH.

Blood. 2014 Feb 6;123(6):843-50. doi: 10.1182/blood-2013-09-529008. Epub 2013 Nov 25.

27.

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.

Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D.

Br J Haematol. 2014 Feb;164(4):608-10. doi: 10.1111/bjh.12648. Epub 2013 Nov 13. No abstract available.

PMID:
24219400
28.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L.

Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.

PMID:
24117365
29.

Target enrichment and high-throughput sequencing of 80 ribosomal protein genes to identify mutations associated with Diamond-Blackfan anaemia.

Gerrard G, Valgañón M, Foong HE, Kasperaviciute D, Iskander D, Game L, Müller M, Aitman TJ, Roberts I, de la Fuente J, Foroni L, Karadimitris A.

Br J Haematol. 2013 Aug;162(4):530-6. doi: 10.1111/bjh.12397. Epub 2013 May 30.

PMID:
23718193
30.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D.

Blood. 2013 Apr 4;121(14):2739-42. doi: 10.1182/blood-2012-11-466037. Epub 2013 Feb 4.

31.

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations.

Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, Awan A, Carter I, Goday-Fernandez A, Langabeer SE, Clench T, Clark J, Evans PA, Grimwade D, Schuh A, McMullin MF, Green AR, Harrison CN, Cross NC; British Committee for Standards in Haematology.

Br J Haematol. 2013 Jan;160(1):25-34. doi: 10.1111/bjh.12075. Epub 2012 Oct 11.

PMID:
23057517
32.
33.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K.

Blood. 2012 Jul 19;120(3):697-8. doi: 10.1182/blood-2012-04-421016. No abstract available.

34.

Fast-mode duplex qPCR for BCR-ABL1 molecular monitoring: innovation, automation, and harmonization.

Gerrard G, Mudge K, Foskett P, Stevens D, Alikian M, White HE, Cross NC, Apperley J, Foroni L.

Am J Hematol. 2012 Jul;87(7):717-20. doi: 10.1002/ajh.23212. Epub 2012 May 6.

35.

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A.

N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.

36.

Thyroid cancer susceptibility polymorphisms: confirmation of loci on chromosomes 9q22 and 14q13, validation of a recessive 8q24 locus and failure to replicate a locus on 5q24.

Jones AM, Howarth KM, Martin L, Gorman M, Mihai R, Moss L, Auton A, Lemon C, Mehanna H, Mohan H, Clarke SE, Wadsley J, Macias E, Coatesworth A, Beasley M, Roques T, Martin C, Ryan P, Gerrard G, Power D, Bremmer C; TCUKIN Consortium, Tomlinson I, Carvajal-Carmona LG.

J Med Genet. 2012 Mar;49(3):158-63. doi: 10.1136/jmedgenet-2011-100586. Epub 2012 Jan 25.

37.

BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.

Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L.

Am J Hematol. 2012 Mar;87(3):298-304. doi: 10.1002/ajh.22272. Epub 2012 Jan 9. Review.

38.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D.

Blood. 2012 Feb 23;119(8):1838-43. doi: 10.1182/blood-2011-10-383000. Epub 2011 Dec 14.

39.

Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, Clark RE, Apperley JF, Milojkovic D, Bua M, Pavlu J, Paliompeis C, Reid A, Rezvani K, Goldman JM, Foroni L.

J Clin Oncol. 2012 Jan 20;30(3):232-8. doi: 10.1200/JCO.2011.38.6565. Epub 2011 Nov 7.

40.

Thyroxine dosing after I131Radioiodine ablation for differentiated thyroid cancer.

Clarke K, Gill V, Gerrard G.

Clin Oncol (R Coll Radiol). 2011 Oct;23(8):559-60. doi: 10.1016/j.clon.2011.04.007. Epub 2011 May 6. No abstract available.

PMID:
21530195
41.

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia.

Foroni L, Wilson G, Gerrard G, Mason J, Grimwade D, White HE, de Castro DG, Austin S, Awan A, Burt E, Clench T, Farruggia J, Hancock J, Irvine AE, Kizilors A, Langabeer S, Milner BJ, Nickless G, Schuh A, Sproul A, Wang L, Wickham C, Cross NC.

Br J Haematol. 2011 Apr;153(2):179-90. doi: 10.1111/j.1365-2141.2011.08603.x. Epub 2011 Mar 8.

PMID:
21382019
42.

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.

Ibrahim AR, Eliasson L, Apperley JF, Milojkovic D, Bua M, Szydlo R, Mahon FX, Kozlowski K, Paliompeis C, Foroni L, Khorashad JS, Bazeos A, Molimard M, Reid A, Rezvani K, Gerrard G, Goldman J, Marin D.

Blood. 2011 Apr 7;117(14):3733-6. doi: 10.1182/blood-2010-10-309807. Epub 2011 Feb 23.

43.

The recurrence rate for low-risk differentiated thyroid cancer is extremely low (0.5% after more than 5 years of follow-up).

Gerrard GE, Mason MT.

Clin Oncol (R Coll Radiol). 2011 Jun;23(5):374-5. doi: 10.1016/j.clon.2011.01.506. Epub 2011 Feb 22. No abstract available.

PMID:
21345658
44.

Duplex quantitative PCR for molecular monitoring of BCR-ABL1-associated hematological malignancies.

Gerrard G, Mudge K, Stewart R, Foskett P, Stevens D, Khorashad JS, Szydlo R, Rezvani K, Marin D, Reid A, Apperley J, Goldman J, Foroni L.

Am J Hematol. 2011 Mar;86(3):313-5. doi: 10.1002/ajh.21954. Epub 2011 Feb 15. No abstract available.

45.

EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors.

Daghistani M, Marin D, Khorashad JS, Wang L, May PC, Paliompeis C, Milojkovic D, De Melo VA, Gerrard G, Goldman JM, Apperley JF, Clark RE, Foroni L, Reid AG.

Blood. 2010 Dec 23;116(26):6014-7. doi: 10.1182/blood-2010-01-264234. Epub 2010 Sep 20.

PMID:
20855863
46.

Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.

Grant H, Jiang X, Stebbing J, Foroni L, Craddock C, Griffiths M, Clark RE, O'Brien S, Khorashad JS, Gerrard G, Wang L, Irving JA, Wang M, Karran L, Dyer MJ, Forrest D, Page K, Eaves CJ, Woolfson A.

Leukemia. 2010 Oct;24(10):1817-21. doi: 10.1038/leu.2010.179. Epub 2010 Aug 26. No abstract available.

PMID:
20739956
47.

Regulation of myeloid leukaemia by the cell-fate determinant Musashi.

Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, Jordan CT, Reya T.

Nature. 2010 Aug 5;466(7307):765-8. doi: 10.1038/nature09171. Epub 2010 Jul 18.

48.

Management of hypocalcaemia in the oncology clinics.

Gerrard G, Rodda S, Anderson J.

Clin Oncol (R Coll Radiol). 2010 Sep;22(7):615-6. doi: 10.1016/j.clon.2010.05.009. No abstract available.

PMID:
20627491
49.

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.

Bazeos A, Marin D, Reid AG, Gerrard G, Milojkovic D, May PC, de Lavallade H, Garland P, Rezvani K, Apperley JF, Goldman JM, Foroni L, Khorashad JS.

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6. No abstract available.

PMID:
20445576
50.

Should we routinely offer a second admission for radioiodine to patients with high-risk differentiated thyroid cancer?

Gerrard GE, O'Toole L, Roberts F.

Clin Oncol (R Coll Radiol). 2010 Mar;22(2):136-9. doi: 10.1016/j.clon.2010.01.002.

PMID:
20152708

Supplemental Content

Loading ...
Support Center